Makers Laboratories Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change

Quality Assessment: Weak Long-Term Fundamentals Persist

Despite the recent upgrade, Makers Laboratories continues to exhibit weak long-term fundamental strength. The company’s operating profits have declined at a compounded annual growth rate (CAGR) of -15.78% over the past five years, signalling deteriorating operational efficiency. Furthermore, the average Return on Equity (ROE) stands at a modest 2.20%, indicating limited profitability relative to shareholders’ funds. This low ROE underscores the company’s struggle to generate adequate returns on invested capital, a critical factor for long-term investor confidence.

Over the last year, the stock’s return of 5.51% marginally matches the Sensex’s 5.52% gain, but this performance masks a severe 82.7% decline in profits, highlighting a disconnect between market price and underlying earnings quality. Such disparity raises concerns about the sustainability of the current valuation and the company’s ability to deliver consistent shareholder value.

Valuation: Premium Despite Profit Declines

Makers Laboratories is currently trading at a Price to Book (P/B) ratio of 1.2, which is considered very expensive relative to its peers and historical averages. This premium valuation is not supported by the company’s fundamentals, given the negative profit growth and low ROE. The stock’s 52-week high of ₹173.70 contrasts with its current price of ₹149.25, suggesting some room for price appreciation, but the valuation premium may limit upside potential unless earnings improve substantially.

The company’s market capitalisation grade is rated 4, reflecting a mid-tier market cap status within the Pharmaceuticals & Biotechnology sector. This positioning may influence investor appetite, especially when compared to larger, more stable peers in the industry.

Financial Trend: Mixed Signals with Recent Quarterly Improvement

While the long-term financial trend remains weak, Makers Laboratories reported positive quarterly results for Q3 FY25-26, which have contributed to the upgrade. Profit Before Tax excluding Other Income (PBT LESS OI) surged by 152.9% to ₹2.82 crores compared to the previous four-quarter average. Net sales reached a quarterly high of ₹35.67 crores, and Profit Before Depreciation, Interest, and Tax (PBDIT) also hit a peak at ₹4.16 crores.

These improvements suggest some operational recovery, although the company’s five-year CAGR in operating profits remains negative. The recent quarterly performance may be an early sign of turnaround, but investors should remain cautious given the broader downward trend in profitability.

Technical Analysis: Key Driver of Upgrade

The primary catalyst for the rating upgrade is the shift in technical indicators from a mildly bearish to a sideways trend. The stock’s technical grade has improved, reflecting a more neutral market stance after a period of weakness. Key technical signals include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, supported by bullish Bollinger Bands on both weekly and monthly timeframes.

However, some mixed signals remain. The monthly MACD and KST (Know Sure Thing) indicators are bearish, while the weekly KST is bullish. The Relative Strength Index (RSI) shows no clear signal on either weekly or monthly charts, and the Dow Theory indicates no definitive trend. Daily moving averages remain mildly bearish, suggesting some short-term caution.

Overall, the technical picture has improved sufficiently to warrant an upgrade from Strong Sell to Sell, reflecting a less negative momentum and potential for stabilisation in the near term.

Stock Performance Relative to Sensex

Makers Laboratories has outperformed the Sensex over several recent periods, notably with a 1-week return of 5.14% versus the Sensex’s -2.53%, and a year-to-date return of 26.32% compared to the Sensex’s -8.23%. Over three years, the stock has gained 35.68%, slightly ahead of the Sensex’s 32.25%. However, over five years, the stock has underperformed significantly with a -35.26% return against the Sensex’s 52.51% gain. Over a decade, the stock’s 151.69% return trails the Sensex’s 217.61%.

This mixed relative performance highlights the stock’s volatility and the challenges it faces in maintaining consistent growth relative to the broader market.

Ownership and Market Position

The majority shareholding in Makers Laboratories remains with promoters, which often provides stability in governance and strategic direction. However, the company’s mid-tier market capitalisation and sector positioning in Pharmaceuticals & Biotechnology place it in a competitive environment where innovation and financial strength are critical for sustained success.

Given the current valuation premium and weak long-term fundamentals, investors should weigh the recent technical improvements against the broader challenges before making investment decisions.

Conclusion: Cautious Optimism Amidst Fundamental Concerns

The upgrade of Makers Laboratories Ltd from Strong Sell to Sell reflects a nuanced view of the company’s prospects. While technical indicators have improved, signalling a potential stabilisation in share price momentum, the underlying financial and valuation metrics remain concerning. Weak long-term profit growth, low ROE, and expensive valuation relative to peers temper enthusiasm.

Investors should monitor upcoming quarterly results closely to assess whether the recent positive trends in sales and profitability can be sustained. Until then, the stock’s rating suggests a cautious stance, recognising some near-term technical recovery but acknowledging significant fundamental headwinds.

Key Metrics Summary:

• Mojo Score: 33.0 (Upgraded from Strong Sell to Sell on 10 Mar 2026)
• Current Price: ₹149.25 (Day Change: +4.99%)
• 52-Week Range: ₹109.00 - ₹173.70
• Operating Profit CAGR (5 years): -15.78%
• Average ROE: 2.20%
• Price to Book Value: 1.2 (Premium valuation)
• Quarterly PBT LESS OI Growth: +152.9% to ₹2.82 crores
• Quarterly Net Sales: ₹35.67 crores (Highest)
• Quarterly PBDIT: ₹4.16 crores (Highest)

Technical Indicators:

• Trend: Shifted from mildly bearish to sideways
• MACD: Weekly Bullish, Monthly Bearish
• Bollinger Bands: Weekly and Monthly Bullish
• Moving Averages: Daily Mildly Bearish
• KST: Weekly Bullish, Monthly Bearish
• RSI: No clear signals
• Dow Theory: No trend

Stock Returns vs Sensex:

• 1 Week: +5.14% vs Sensex -2.53%
• 1 Month: +4.12% vs Sensex -7.20%
• Year-to-Date: +26.32% vs Sensex -8.23%
• 1 Year: +5.51% vs Sensex +5.52%
• 3 Years: +35.68% vs Sensex +32.25%
• 5 Years: -35.26% vs Sensex +52.51%
• 10 Years: +151.69% vs Sensex +217.61%

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →